CardioGenesis PMR Not Approvable; Firm May Seek Strategic Investor/Partner
This article was originally published in The Gray Sheet
Executive Summary
CardioGenesis may look for a strategic partner to support its continued pursuit of approval for laser percutaneous myocardial revascularization (PMR)
You may also be interested in...
CardioGenesis’ PMR On Deck For FDA Dispute Resolution Panel Review
CardioGenesis is retaining Covington & Burling to help prepare for its upcoming dispute resolution panel. The regulatory law firm consulted Lifecore Biomedical in the only other MDDRP review
CardioGenesis’ PMR On Deck For FDA Dispute Resolution Panel Review
CardioGenesis is retaining Covington & Burling to help prepare for its upcoming dispute resolution panel. The regulatory law firm consulted Lifecore Biomedical in the only other MDDRP review
PMR Adverse Events, Elusive Efficacy Endpoints Cited In Panel Rejection
The reliance on hospitalization for angina as a safety endpoint in the clinical trials of CardioGenesis' Eclipse PMR (percutaneous myocardial revascularization) device masked the rate of significant adverse events related to the procedure, according to FDA's Circulatory System Devices Panel.